Clinical trials: Significant Prostate Cancer
Prostate Cancer (Diagnosis), Clinically Significant Prostate Cancer
Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction
This is a multicenter observational study. A deep learning model integrated with multimodal imaging and digital pathology spatial registration is built based on preoperative multiparametric magnetic resonance imaging, transrectal…
- Trial name
- NCT07614256
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Guangxi Medical University
Prostate Carcinoma
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen [PSMA] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can…
- Trial name
- NCT07164027
- Testing
- Biopsy of Prostate, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Comparing MRI-Ultrasound Fusion and Cognitive-guided Biopsy for the Detection of csPCa: the PROFUSION Trial
This study is an international multicentre RCT to compare the linically significant prostate cancer (csPCa) detection of cognitive-guided and MRI-USG guided biopsies in men with suspicious MRI lesion.
- Trial name
- NCT06303622
- Testing
- MRI-USG fusion approach, Cognitive-guided approach
- Where
- Hong Kong
- Volunteers
- 1,620 people
- Sponsor
- Chinese University of Hong Kong
Prostate Carcinoma
Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer
This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa).
- Trial name
- NCT06024772
- Testing
- ultiparametric Magnetic Resonance Imaging, Perflutren lipid microsphere, Transrectal Ultrasound
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 300 people
- Sponsor
- Thomas Jefferson University
Prostate Cancer
The Development and Validation of MRI-AI-based Predictive Models for csPCa
This study retrospectively included patients who underwent prostate magnetic resonance imaging (MRI) and subsequent ultrasound-guided prostate biopsy at Peking University First Hospital from January 2019 to December 2023, and…
- Trial name
- NCT06842264
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking University First Hospital
Prostate Cancer, Multiple Myeloma
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering…
- Conditions
- Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT04731844
- Testing
- Curcumin plus Piperine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Prostate Cancer
Validation of a Machine Learning Model Based on MR for the Prediction of Prostate Cancer
The goal of this observational study is to validate a clinically significant predictive machine learning model based on the processing of images RMmp (Multiparametric Magnetic Resonance Imaging).
- Trial name
- NCT06773598
- Where
- Italy
- Volunteers
- 1,100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prostate Cancer
Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Combination of PSA/DRE and Multi Parametric Magnetic Resonance Imaging
This randomized prospective multi center study is designed to confirm a new diagnostic pathway in primary diagnosis of clinically significant prostate cancer by combination of serum levels of prostate specific antigen (PSA)…
- Trial name
- PRIMA (NCT04993508)
- Testing
- PSA test, multiparametric prostate Magnetic Resonance Imaging (mpMRI), targeted MRI/US fusion-guided biopsy
- Volunteers
- 1,908 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Prostate Cancer
18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
This project aims to evaluate the role of fully hybrid PET/MRI with 18F-PSMA and multiparametric MR imaging (mpMRI) as one-stop approach for the diagnosis of clinically significant prostate cancer (csPCa).
- Trial name
- NCT05815316
- Testing
- 18F-PSMA-1007
- Sponsor
- IRCCS San Raffaele
Multiparametric MRI, Lesion PI-RADS 3
The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)
Prostate Specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT), an imaging modality focusing on a protein overexpressed by prostate cancer cells, has revolutionised the staging of both newly…
- Trial name
- PANDORA (NCT06867588)
- Testing
- PSMA PET
- Where
- Belgium
- Volunteers
- 68 people
- Sponsor
- Jules Bordet Institute
Anemia, Metastatic Cancer
Proteases in Patients With Prostate Cancer That Has Spread to the Bone
RATIONALE: Collecting and storing samples of bone marrow and tissue from patients to test in the laboratory may help the study of cancer.
- Conditions
- Anemia, Metastatic Cancer, Myelodysplastic Syndromes, Precancerous Condition
- Trial name
- NCT00899665
- Testing
- fluorescence in situ hybridization, microarray analysis, molecular diagnostic method
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer (Adenocarcinoma)
Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions
The goal of this observational study is to assess the chance to predict prostate cancer with the analysis of specific values found in images obtained from RMmp (multiparametric magnetic resonance imaging) of patients who went…
- Trial name
- NCT06774781
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prostate Cancer
Biparametric MRI for Detection of Significant Prostate Cancer
Our aim is to develop a new diagnostic approach to improve the diagnosis of men suspicious of having significant prostate cancer (sPCa).
- Trial name
- BIDOC (NCT02584179)
- Testing
- Biparametric MRI before biopsy
- Where
- Denmark
- Volunteers
- 1,063 people
- Sponsor
- Herlev Hospital
Prostate Cancer, Risk Assessment
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria
This study is a pilot trial that builds on findings from the validation of prostate cancer risk calculators in Nigerian men. The goal of the overall study is to improve the early detection of prostate cancer in a high-risk…
- Conditions
- Prostate Cancer, Risk Assessment, Clinical Decision Support Systems, Predictive Value of Tests
- Trial name
- PROACT (NCT07733440)
- Testing
- (a) Training and (b) Supported risk assessment
- Where
- Nigeria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Ahmadu Bello University
Prostate Cancer
Radical Prostatectomy Without Prior Biopsy
This pilot comparative study will evaluate a one-stage diagnostic and surgical strategy for patients with a high probability of clinically significant prostate cancer who have not undergone a separate preoperative prostate…
- Trial name
- NCT07819760
- Testing
- Transperineal Fusion-Targeted Prostate Biopsy With Intraoperative Frozen Section Examination, Robot-Assisted Radical Prostatectomy With Pelvic Lymph Node Dissection, Standard Transperineal Fusion Prostate Biopsy
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Botkin Hospital